Although with significant diagnostic and therapeutic potential for RCC, only a limited number of mouse anti-human CAIX antibodies have been identified [13], [16], [37] and essentially only one humanized anti-CAIX mAb has been evaluated in the clinical setting. Here, CA9 is linked to renal cell carcinoma.